Seres Therapeutics Inc [NASDAQ: MCRB] gained 7.98% or 0.08 points to close at $1.03 with a heavy trading volume of 5791111 shares.
The daily chart for MCRB points out that the company has recorded 6.13% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 4.06M shares, MCRB reached to a volume of 5791111 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Seres Therapeutics Inc [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $3.34 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 26, 2023. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on April 21, 2023, representing the official price target for Seres Therapeutics Inc stock. Previously, the target price had yet another drop from $24 to $7, while Goldman kept a Sell rating on MCRB stock.
The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.13, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 424.19.
Trading performance analysis for MCRB stock
Seres Therapeutics Inc [MCRB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.65. With this latest performance, MCRB shares gained by 12.61% in over the last four-week period, additionally plugging by 6.13% over the last 6 months – not to mention a drop of -68.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 58.33, with the RSI for the last a single of trading hit 67.98, and the three-weeks RSI is set at 54.43 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 1.0073, while it was recorded at 0.8974 for the last single week of trading, and 0.9930 for the last 200 days.
Seres Therapeutics Inc [MCRB]: A deeper dive into fundamental analysis
Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.89 and a Current Ratio set at 1.38.
An analysis of Institutional ownership at Seres Therapeutics Inc [MCRB]
There are presently around $45.42%, or 48.03%% of MCRB stock, in the hands of institutional investors. The top three institutional holders of MCRB stocks are: FLAGSHIP PIONEERING INC. with ownership of 23.12 million shares, which is approximately 15.8226%. FMR LLC, holding 22.72 million shares of the stock with an approximate value of $$16.44 million in MCRB stocks shares; and FMR LLC, currently with $$4.55 million in MCRB stock with ownership which is approximately 4.3023%.
